Search Browse Earnings

Humacyte, Inc. — SlamSEC

Humacyte, Inc.

Nasdaq:HUMANasdaq:HUMAW

Biological Products, (No Diagnostic Substances)·DURHAM, NC

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

—

Adj. EBITDA

-$94.4M

FY 2024

Net Income

-$110.8M

FY 2024

EPS (Diluted)

-$1.07

FY 2024

Stock Price

$1.24

+3.3%

2026-03-10

52W Range

$0.88 – $3.36

P/E Ratio

-1.2x

Market Cap

$232.2M

Cash

$80.4M

FY 2024

Total Debt

$30.0M

FY 2021

Net Cash

$50.4M

FY 2021

Enterprise Value

$181.8M

Debt / EBITDA

0.5x

FY 2024

EV / EBITDA

-1.9x

Employees

—

CEO

Niklason Laura E

CFO

Sander Dale A.